Novavax completes FDA submission for COVID-19 vaccine


Novavax has submitted final data to the FDA for its COVID-19 vaccine and plans to seek emergency use authorization for its protein-based vaccine this month. "Novavax is committed to delivering our protein-based vaccine in the United States, where the COVID-19 pandemic continues to evolve with the emergence of new variants," Novavax President and CEO Stanley Erck said.

Full story:

AIChE SmartBrief

Chemical engineering news

Designed specifically for chemical engineers, AIChE SmartBrief is a FREE weekly e-mail newsletter. It helps chemical engineers stay informed on the business and technology developments affecting our profession.